Dr. Shu’s research primarily focuses on identifying novel genetic and molecular markers for cancer risk, with the goal of better understanding tumorigenesis and providing novel tools for risk assessment. Dr. Shu is actively participating in multiple international consortia including the Breast Cancer Association Consortium, the Asia Breast Cancer Consortium, the Genetics and Epidemiology of Colorectal Cancer Consortium. Dr. Shu recently received an R00 grant, which aims to provide new insights into the etiology of colorectal cancer and identify novel risk biomarkers for this malignancy via integrated omics approaches. He is also an active investigator in three large prospective cohorts, the Shanghai Women’s Health Study (SWHS), the Shanghai Men’s Health Study (SMHS), and the Southern Community Cohort Study (SCCS), leading several prospective metabolomics and proteomics projects in these cohorts. These projects provided solid preliminary data to support further investigations to uncover novel risk biomarkers for colorectal, pancreatic, and gastric cancers. With the contribution of resources from several established prospective cohorts, including SWHS/SMHS, SCCS, the Multiethnic Cohort Study, the European Prospective Investigation into Cancer and Nutrition Study, and the Women’s Health Initiative, Dr. Shu has formed an international consortium to investigate the relationship between perturbation of blood metabolome and risk of incident gastric cancer. After joining the department in August, Dr. Shu has also extended his interest to patient-oriented research by contributing his expertise in genetic and molecular epidemiology.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Xiang Shu discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures